Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Commentary: The “efficacy window” phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis

  • William V. McCall1
  • Neil A. Burton2
  • Björn Steiniger-Brach2
  1. 1Department of Psychiatry and Health Behavior, Medical College of Georgia (MCG), Augusta University
  2. 2Idorsia Pharmaceuticals Ltd.
Open at sourcePDFDOICite

Related

  1. Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
    Dorota Bartkowiak, Barlomiej Jakubczyk, Adam Lasota +7
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Splenic Enlargement During Neoadjuvant Chemotherapy for Gastric Cancer: Treatment-Related Phenomenon or Prognostic Biomarker?
    Ezgi Altınsoy, Veysel Cem Özcan, Abdurrahman Başpınar +4
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  3. Comprehensive management of chronic insomnia in Spain: a multidisciplinary modified RAND/UCLA consensus with recommendations on daridorexant
    Ainhoa Álvarez-Ruiz-Larrinaga, Lorenzo Armenteros, Carmen Bellido +4
    Frontiers in PsychiatryPeer-reviewedCC BY 4.0Full textPsychiatry & mental healthCrossrefEurope PMCPMC
  4. Human dignity and its associations with self efficacy and treatment adherence in adults with type 2 diabetes in Iran
    Yasaman Fallah, Narges Hashemi, Mahrokh Keshvari +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismCrossref
  5. Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
    Zhe Fu, Victoria Jackson-Patel, Kathryn Farrand +7
    Journal for immunotherapy of cancerPeer-reviewedCC BY-NCFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{mccall2026commentary,
  title = {{Commentary: The “efficacy window” phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis}},
  author = {William V. McCall and Neil A. Burton and Björn Steiniger-Brach},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1976948},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1976948/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Commentary: The “efficacy window” phenomenon of daridorexant in insomnia treatment: a dose-dependent time-course meta-analysis
AU  - William V. McCall
AU  - Neil A. Burton
AU  - Björn Steiniger-Brach
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1976948
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1976948/full
SN  - 1663-9812
ER  -